201 related articles for article (PubMed ID: 34669647)
1. State of the art and future directions in the systemic treatment of medullary thyroid cancer.
Jager EC; Broekman KE; Kruijff S; Links TP
Curr Opin Oncol; 2022 Jan; 34(1):1-8. PubMed ID: 34669647
[TBL] [Abstract][Full Text] [Related]
2. LIBRETTO-531: a phase III study of selpercatinib in multikinase inhibitor-naïve
Wirth LJ; Brose MS; Elisei R; Capdevila J; Hoff AO; Hu MI; Tahara M; Robinson B; Gao M; Xia M; Maeda P; Sherman E
Future Oncol; 2022 Sep; 18(28):3143-3150. PubMed ID: 35969032
[TBL] [Abstract][Full Text] [Related]
3. Medullary Thyroid Cancer - Feature Review and Update on Systemic Treatment.
Dabelić N; Jukić T; Fröbe A
Acta Clin Croat; 2020 Jun; 59(Suppl 1):50-59. PubMed ID: 34219884
[TBL] [Abstract][Full Text] [Related]
4. Clinical utility of genetic diagnosis for sporadic and hereditary medullary thyroid carcinoma.
Elisei R; Bottici V; Cappagli V; Ramone T; Tacito A; Ciampi R; Romei C
Ann Endocrinol (Paris); 2019 Jun; 80(3):187-190. PubMed ID: 31053251
[TBL] [Abstract][Full Text] [Related]
5. Medullary Thyroid Cancer: Updates and Challenges.
Gild ML; Clifton-Bligh RJ; Wirth LJ; Robinson BG
Endocr Rev; 2023 Sep; 44(5):934-946. PubMed ID: 37204852
[TBL] [Abstract][Full Text] [Related]
6. Germline RET mutation carriers in Japanese patients with apparently sporadic medullary thyroid carcinoma: A single institution experience.
Kihara M; Miyauchi A; Yoshioka K; Oda H; Nakayama A; Sasai H; Yabuta T; Masuoka H; Higashiyama T; Fukushima M; Ito Y; Kobayashi K; Miya A
Auris Nasus Larynx; 2016 Oct; 43(5):551-5. PubMed ID: 26837867
[TBL] [Abstract][Full Text] [Related]
7. A Contemporary Review of the Treatment of Medullary Thyroid Carcinoma in the Era of New Drug Therapies.
Seib CD; Beck TC; Kebebew E
Surg Oncol Clin N Am; 2023 Apr; 32(2):233-250. PubMed ID: 36925182
[TBL] [Abstract][Full Text] [Related]
8. Genomics and Epigenomics of Medullary Thyroid Carcinoma: From Sporadic Disease to Familial Manifestations.
Barletta JA; Nosé V; Sadow PM
Endocr Pathol; 2021 Mar; 32(1):35-43. PubMed ID: 33492588
[TBL] [Abstract][Full Text] [Related]
9. Management of Advanced Medullary Thyroid Carcinoma: Current Systemic Therapy Options.
Jara MA
Crit Rev Oncog; 2024; 29(3):83-90. PubMed ID: 38683155
[TBL] [Abstract][Full Text] [Related]
10. Systemic treatment and management approaches for medullary thyroid cancer.
Ernani V; Kumar M; Chen AY; Owonikoko TK
Cancer Treat Rev; 2016 Nov; 50():89-98. PubMed ID: 27664392
[TBL] [Abstract][Full Text] [Related]
11. Patient-Reported Outcomes with Selpercatinib Treatment Among Patients with RET-Mutant Medullary Thyroid Cancer in the Phase I/II LIBRETTO-001 Trial.
Wirth LJ; Robinson B; Boni V; Tan DSW; McCoach C; Massarelli E; Hess LM; Jen MH; Kherani J; Olek E; Subbiah V
Oncologist; 2022 Feb; 27(1):13-21. PubMed ID: 34516023
[TBL] [Abstract][Full Text] [Related]
12. The Evolving Treatment Landscape of Medullary Thyroid Cancer.
Laganà M; Cremaschi V; Alberti A; Vodopivec Kuri DM; Cosentini D; Berruti A
Curr Treat Options Oncol; 2023 Dec; 24(12):1815-1832. PubMed ID: 37979019
[TBL] [Abstract][Full Text] [Related]
13. Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study.
Subbiah V; Hu MI; Wirth LJ; Schuler M; Mansfield AS; Curigliano G; Brose MS; Zhu VW; Leboulleux S; Bowles DW; Baik CS; Adkins D; Keam B; Matos I; Garralda E; Gainor JF; Lopes G; Lin CC; Godbert Y; Sarker D; Miller SG; Clifford C; Zhang H; Turner CD; Taylor MH
Lancet Diabetes Endocrinol; 2021 Aug; 9(8):491-501. PubMed ID: 34118198
[TBL] [Abstract][Full Text] [Related]
14. Pralsetinib in Patients with Advanced/Metastatic Rearranged During Transfection (RET)-Altered Thyroid Cancer: Updated Efficacy and Safety Data from the ARROW Study.
Subbiah V; Hu MI; Mansfield AS; Taylor MH; Schuler M; Zhu VW; Hadoux J; Curigliano G; Wirth L; Gainor JF; Alonso G; Adkins D; Godbert Y; Ahn MJ; Cassier PA; Cho BC; Lin CC; Zalutskaya A; Barata T; Trask P; Scalori A; Bordogna W; Heinzmann S; Brose MS
Thyroid; 2024 Jan; 34(1):26-40. PubMed ID: 38009200
[No Abstract] [Full Text] [Related]
15. A comprehensive overview of the role of the RET proto-oncogene in thyroid carcinoma.
Romei C; Ciampi R; Elisei R
Nat Rev Endocrinol; 2016 Apr; 12(4):192-202. PubMed ID: 26868437
[TBL] [Abstract][Full Text] [Related]
16. Current understanding and management of medullary thyroid cancer.
Roy M; Chen H; Sippel RS
Oncologist; 2013; 18(10):1093-100. PubMed ID: 24037980
[TBL] [Abstract][Full Text] [Related]
17. Screening of RET gene mutations in Chinese patients with medullary thyroid carcinoma and their relatives.
Wang J; Zhang B; Liu W; Zhang Y; Di X; Yang Y; Yan D
Fam Cancer; 2016 Jan; 15(1):99-104. PubMed ID: 26254625
[TBL] [Abstract][Full Text] [Related]
18. MANAGEMENT OF ENDOCRINE DISEASE: Medullary thyroid cancer: from molecular biology and therapeutic pitfalls to future targeted treatment perspectives.
Saltiki K; Simeakis G; Karapanou O; Alevizaki M
Eur J Endocrinol; 2022 Sep; 187(3):R53-R63. PubMed ID: 35895692
[TBL] [Abstract][Full Text] [Related]
19. Genetics of medullary thyroid cancer: An overview.
Accardo G; Conzo G; Esposito D; Gambardella C; Mazzella M; Castaldo F; Di Donna C; Polistena A; Avenia N; Colantuoni V; Giugliano D; Pasquali D
Int J Surg; 2017 May; 41 Suppl 1():S2-S6. PubMed ID: 28506408
[TBL] [Abstract][Full Text] [Related]
20. Cabozantinib and vandetanib for unresectable locally advanced or metastatic medullary thyroid cancer: a systematic review and economic model.
Tappenden P; Carroll C; Hamilton J; Kaltenthaler E; Wong R; Wadsley J; Moss L; Balasubramanian S
Health Technol Assess; 2019 Feb; 23(8):1-144. PubMed ID: 30821231
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
